The McGill University Health Centre (MUHC) has launched a Phase 1 clinical trial evaluating a novel radioligand therapy for patients with HER2-positive solid tumors. This trial, the first of its kind in Canada for this specific molecular target, utilizes a radioactive molecule designed to bind directly to HER2 proteins on cancer cells, delivering localized radiation to destroy the tumor while sparing surrounding healthy tissue.
How Does Radioligand Therapy Work for HER2 Cancers?
Radioligand therapy combines a targeting molecule—in this case, one that seeks out the HER2 protein—with a therapeutic radioisotope. According to the Society of Nuclear Medicine and Molecular Imaging, once the radioligand binds to the receptor on the cancer cell, it is internalized, allowing the radioactive payload to damage the cell’s DNA. This targeted approach differs significantly from conventional systemic chemotherapy, which affects rapidly dividing cells throughout the entire body. By focusing radiation internally at the molecular level, clinicians aim to increase the therapeutic index, potentially reducing the side effects commonly associated with traditional cancer treatments.
Why This Trial Matters for HER2-Positive Patients
While HER2-targeted therapies like trastuzumab have revolutionized the treatment of breast cancer, many patients eventually develop resistance to these drugs or present with tumors that do not respond to standard monoclonal antibodies. The MUHC trial, led by principal investigator Dr. Ariane Marelli and her team, seeks to address this unmet need. By utilizing a different mechanism of action—radiation delivery rather than receptor blockade—this therapy may provide a viable option for patients who have exhausted standard-of-care treatments. The trial is currently recruiting participants to determine the safety, dosage, and preliminary efficacy of the compound in a human population.
What Is the Difference Between Radioligand Therapy and ADCs?
Patients and clinicians often compare this new approach to Antibody-Drug Conjugates (ADCs), such as trastuzumab deruxtecan. While both methods utilize the HER2 receptor as a "docking station" to deliver a payload, the mechanisms of destruction differ:
| Feature | Radioligand Therapy | Antibody-Drug Conjugates (ADCs) |
|---|---|---|
| Payload | Radioactive isotope | Chemotherapy agent |
| Mechanism | DNA damage via radiation | Inhibition of cell division |
| Range | Cross-fire effect (damages neighbors) | Targeted cell only |
| Delivery | Intravenous injection | Intravenous infusion |
According to the National Cancer Institute, the "cross-fire" effect of radioligand therapy allows the radiation to affect not only the targeted cell but also neighboring cancer cells within a small radius, which can be particularly effective in tumors that have heterogeneous HER2 expression.
What Are the Next Steps for Participants?
Phase 1 clinical trials are primarily designed to evaluate safety and identify the maximum tolerated dose. Patients enrolled in the MUHC study will undergo rigorous monitoring, including frequent imaging and blood work, to assess how the body processes the radioligand and to document any adverse reactions. If the trial demonstrates a favorable safety profile and early signs of tumor regression, the study will move into larger Phase 2 and 3 trials. Interested patients should consult their oncology team to determine if their specific tumor profile meets the eligibility criteria for this study, as trial participation requires precise molecular diagnostic testing to confirm HER2 status.